Abstract
Background This study investigates the efficacy and the feasibility of a chemotherapy regimen with topotecan plus vincristine and doxorubicin (TVD) given on an individually tailored basis to patients with refractory/recurrent rhabdomyosarcoma (RMS). Patients and methods Nine patients received TVD therapy at relapse, and six were assessable for response. Results All the six patients experienced objective response after two cycles of chemotherapy: one minor response, four partial response, and one complete response. Conclusions The value of our study is severely limited by the small number of cases, the single-institutional setting and the individually tailored treatment, but we nonetheless confirmed the feasibility and tolerability of topotecan-based chemotherapy in RMS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gurney JG, Young JL, Roffers SD. Soft tissue sarcomas. In: Gloecker LA, Smith MA, editors. SEER pediatric monograph cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. Bethesda, MD: National Cancer Institute; 1999. p. 111–24.
Crist W, et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610–30.
Baker S, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 1988;6:308–14.
Stewart C, Zamboni W, Crom W, Houghton P. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs. 1996;14:37–47. doi:10.1007/BF00173681.
National Cancer Institute. NCI common toxicity criteria, version 1. Investigator’s handbook: a manual of participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute. Bethesda, MD: U.S. Department of Health and Human Services, Public Heath Service, National Institute of Health; 1993.
Thompson J, Stewart C, Houghton P. Animal models for studying the action of topoisomerase-I target drugs. Biochim Biophys Acta. 1998;1400:301–19.
Houghton PJ, et al. Evaluation of 9-dimethyminomethyl-10hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol. 1992;31:229–39. doi:10.1007/BF00685553.
Rewinky K, Verweij J. Review of Phase I clinical studies with topotecan. Semin Oncol. 1998;24:3–20.
Tubergen DG, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) of topotecan using a five-days course in children with refractory solid tumors: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 1996;18:352–61. doi:10.1097/00043426-199611000-00004.
Nitschke R, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Ped Hematol Oncol. 1998;20:315–8. doi:10.1097/00043426-199807000-00006.
Pappo AS, et al. Up-front window trial of topotecan in previously untreated children and adolescents with matastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 2001;19:213–9.
Saylors RL, et al. Pediatric oncology group: cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors. A Pediatric Oncology Group Phase II Study. J Clin Oncol. 2001;19:3463–9.
Walterhouse DO, et al. Efficacy of topotecan and cyclophosphamide given in Phase II window trial in children with newly diagnosed matastatic rhabdomyosarcoma: a Children’s Oncology Group Study. J Clin Oncol. 2004;22:1398–403. doi:10.1200/JCO.2004.05.184.
Lager JJ, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol. 2006;24:3415–22. doi:10.1200/JCO.2005.01.9497.
Breitfeld PP. Analysis of the therapeutic first-line Phase II window trials in rhabdomyosarcoma. Educational Book, American Society of Clinical Oncology Annual Meeting, Chicago, 2007; p. 607–10.
Arndt CA, et al. Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG Study. Proc Am Soc Clin Oncol. 2007;25(188) (abstract 9509).
Garaventa A, et al. A phase II Study of topotecan with vincristine and doxorubicine in children with recurrent/refractory neuroblastoma. Cancer. 2003;98:2488–94. doi:10.1002/cncr.11797.
Rowinsky EK, Kaufmann SH. Topotecan in combination chemiotheraphy. Semin Oncol. 1997;24:S20-11–S20-26.
Kim R, et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer. 1992;50:760–6. doi:10.1002/ijc.2910500516.
Thompson J, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999;5:3617–31.
Cheung MF, Chatterjee S, Berger NA. Schedule-depend cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res. 1994;6:269–79.
Jonsson E, Fridborg H, Nygren P. Synergistic interactions of combination of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol. 1998;54:509–14. doi:10.1007/s002280050505.
Acknowledgment
This research was partly funded by the Associazione Bianca Garavaglia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meazza, C., Casanova, M., Zaffignani, E. et al. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Med Oncol 26, 67–72 (2009). https://doi.org/10.1007/s12032-008-9085-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-008-9085-8